TITLE

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genolype 2 chronic hepatitis C

AUTHOR(S)
Ming-lung Yu; Chio-yen Dai; Jee-fu Huang; Nai-jen Hou; Li-po Lee; Ming-yen Hsieh; Chang-fu Chiu; Zu-yau Lin; Shinn-cherng Chen; Ming-yuh Hsieh; Liang-yen Wang; Wen-yu Chang; Wan-long Chuang
PUB. DATE
April 2007
SOURCE
Gut;Apr2007, Vol. 56 Issue 4, p553
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The recommended treatment for patients infected with hepatitis C virus genotype 2 (HCV2) is pegylated interferon (peginterferon) and ribavirin for 24 weeks. Aim: To assess whether a shorter 1 6-week treatment is as effective as a standard 24-week treatment. Methods: Patients with HCV2 infection were randomised in a 1:2 ratio to either 16 weeks (n=50) or 24 weeks (n = 100) of treatment with peginterferon α-2a (180 µg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period. A rapid virological response (RVR) was defined as seronegative for HCV RNA at 4 weeks of treatment, and the primary end point, sustained virological response (SVR), as seronegative for HCV RNA at the 24-week follow-up. Results: The rate of RVR and SVR was 86% (43/50, 95% confidence interval (CI) 76% to 96%) and 94% (47/ 50, CI 87% to 100%), respectively, in the 16-week group, which was comparable to 87% (87/100, CI 80% to 94%) and 95% (95/100, CI 91% to 99%) in the 24-week group. Patients with RVR had a significantly higher SVR rate than patients without RVR in both 16-week (100% vs 57%, p = 0.015) and 24-week groups (98% vs 77%, p=0.002). Multivariate analysis showed that RYR and age were independent factors associated with SVR. Both treatment arms were equally well tolerated. The incidence of alopecia was significantly higher in the 24-week group (49%) than in the 16-week group (20%, p=0.001). Conclusion: 16 weeks and 24 weeks of peginterferon treatment with weight-based ribavirin at a dose of 1000-1200 mg/day provided equal efficacy in patients with HCV2 who achieved RVR at 4 weeks.
ACCESSION #
24767585

 

Related Articles

  • Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. McHutchison, John G.; Lawitz, Eric J.; Shiffman, Mitchell L.; Muir, Andrew J.; Galler, Greg W.; McCone, Jonathan; Nyberg, Lisa M.; Lee, William M.; Ghalib, Reem H.; Schiff, Eugene R.; Galati, Joseph S.; Bacon, Bruce R.; Davis, Mitchell N.; Mukhopadhyay, Pabak; Koury, Kenneth; Noviello, Stephanie; Pedicone, Lisa D.; Brass, Clifford A.; Albrecht, Janice K.; Sulkowski, Mark S. // New England Journal of Medicine;8/6/2009, Vol. 361 Issue 6, p580 

    Background: Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. Methods: At 118 sites, patients who had HCV genotype 1...

  • Extended-therapy duration for chronic hepatitis C, genotype 1: The long and the short of it. Pearlman, Brian L.; Papatheodoridis, George V.; Tsubota, Akihito // World Journal of Gastroenterology;6/21/2008, Vol. 14 Issue 23, p3621 

    With pegylated interferon and ribavirin, more than half of all chronically-infected hepatitis C patients can achieve a sustained virologic response; however, patients with genotype 1 infections and those with other poor prognostic factors have relatively inferior treatment response rates. Since...

  • Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon +ribavirin treatment outcomes in Chronic Hepatitis C patients. Akram, Madiha; Idrees, Muhammad; Zafar, Shamail; Hussain, Abrar; Butt, Sadia; Afzal, Samia; Rehman, Irshad-ur; Liaqat, Ali; Saleem, Sana; Ali, Muhammad; Butt, Azeem // Virology Journal;2011, Vol. 8 Issue 1, p234 

    Background: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). PegIFN/ribavirin has increased rate of sustained...

  • Characterization of Hepatitis C Virus genotype 3a Hypervariable region 1 in patients achieved rapid virological response to alpha interferon and Ribavirin Combination therapy. Akram, Madiha; Idrees, Muhammad; Hussain, Abrar; Afzal, Samia; Ilyas, Muhammad; Zafar, Shamail; Aftab, Mahwish; Badar, Sadaf; Khubaib, Bushra // Virology Journal;2011, Vol. 8 Issue 1, p253 

    Background: Hepatitis C virus roots a chronic liver disease. Currently approved treatment strategy includes administration of alpha interferon and ribavirin combined therapy for 24-48 weeks. One of the predictor of sustained virological response is an early virological response to treatment...

  • HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. C Nelson Hayes // Gut;Feb2011, Vol. 60 Issue 2, p261 

    BACKGROUND AND AIMS: A number of recent studies have shown that human polymorphisms near the IL28B type III interferon (IFNλ) gene influence the response to peg-interferon plus ribavirin combination therapy for infection with chronic hepatitis C virus (HCV). Viral polymorphisms, including...

  • IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C. Estrabaud, Emilie; Appourchaux, Kevin; Bièche, Ivan; Carrat, Fabrice; Lapalus, Martine; Lada, Olivier; Martinot-Peignoux, Michelle; Boyer, Nathalie; Marcellin, Patrick; Vidaud, Michel; Asselah, Tarik // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Although, the treatment of chronic hepatitis C (CHC) greatly improved with the use of direct antiviral agents, pegylated-interferon (PEG-IFN) plus ribavirin remains an option for many patients, worldwide. The intra-hepatic level of expression of interferon stimulated genes (ISGs) and the...

  • Evaluacija genotipa hepatitis C virusa i njegov utjecaj na terapijski odgovor pegiliranim interferonom α 2a (40)kD u kombinaciji sa ribavirinom. Vukobrat-Bijedić, Zora; Husić-Selimović, Amina; Radović, Svjetlana; Gornjaković, Srđan; Gogov, Bisera; Zubčević, Nadja; Bilalović, Nurija; Koluder, Nada // Medicinski Arhiv;2007, Vol. 61 Issue 4, p221 

    The aim of our study was to determine the genotypes of viral hepatitis C. We examined 54 patients with chronic hepatitis C who were treated at Gastroenterohepatology Department University of Sarajevo. We also monitored effects of therapeutical results in same group of patients. Polymerasa chain...

  • Chronic Hepatitis C: Viral Clearance Several Months after Discontinuation of Therapy in Two Non-responders. Denis, J.; Rautou, P. E.; Lambare, B.; Herbert, S.; Auray-Cartier, V.; Asselah, T. // Infection;Jun2007, Vol. 35 Issue 3, p197 

    When hepatitis C virus (HCV) infection becomes chronic, spontaneous viral eradication is a rare event. We report two patients with chronic hepatitis C, non-responders to standard interferon alone. They were treated with Pegylated interferon plus ribavirin. At the end of therapy, HCV RNA was...

  • Inhibition of Hepatitis C Virus Replication by Intracellular Delivery of Multiple siRNAs by Nanosomes. Chandra, Partha K; Kundu, Anup K; Hazari, Sidhartha; Chandra, Sruti; Bao, Lili; Ooms, Tara; Morris, Gilbert F; Wu, Tong; Mandal, Tarun K; Dash, Srikanta // Molecular Therapy;Sep2012, Vol. 20 Issue 9, p1724 

    Sustained antiviral responses of chronic hepatitis C virus (HCV) infection have improved recently by the use of direct-acting antiviral agents along with interferon (IFN)-α and ribavirin. However, the emergence of drug-resistant variants is expected to be a major problem. We describe here a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics